Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Repligen Co. (NASDAQ:RGEN) has earned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $196.70.

Several equities analysts recently weighed in on RGEN shares. KeyCorp increased their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Stifel Nicolaus increased their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Finally, JPMorgan Chase & Co. increased their target price on Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th.

Insider Activity

In other news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,597 shares of company stock worth $5,039,532. 1.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Hedge funds have recently bought and sold shares of the business. Fortis Capital Advisors LLC acquired a new stake in Repligen during the 4th quarter valued at approximately $35,000. Park Place Capital Corp lifted its holdings in Repligen by 90.2% during the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after buying an additional 120 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares during the last quarter. Signaturefd LLC lifted its holdings in Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after buying an additional 86 shares during the last quarter. Finally, Principal Securities Inc. bought a new position in Repligen during the 4th quarter worth approximately $48,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Up 0.0 %

Shares of NASDAQ:RGEN opened at $176.08 on Friday. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13. The stock’s fifty day simple moving average is $192.65 and its 200-day simple moving average is $172.94. The company has a market capitalization of $9.83 billion, a P/E ratio of 244.56, a P/E/G ratio of 5.70 and a beta of 1.02.

Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. During the same period in the prior year, the business posted $0.68 earnings per share. The firm’s revenue for the quarter was down 16.6% compared to the same quarter last year. As a group, equities research analysts forecast that Repligen will post 1.46 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.